Navigation Links
SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
Date:5/17/2011

NEW YORK, May 17, 2011 /PRNewswire/ -- SyntheZyme, a sustainable chemical company founded by Richard Gross, the Herman F. Mark chair and professor of chemical and biological sciences at Polytechnic Institute of New York University (NYU-Poly), has received a $475,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation.  These competitive awards provide federal support for small, highly innovative technology businesses.

(Logo:  http://photos.prnewswire.com/prnh/20091027/NY99197LOGO)

This is the second SBIR grant for SyntheZyme. The Phase I grant, awarded in January 2010, provided funding to demonstrate the efficacy of one of SyntheZyme's core innovations — a biopesticide developed from a modified yeast strain that can protect grain and produce crops without the use of harmful chemical agents.

Due to tightened regulations and heightened concerns about the health hazards of synthetic chemical pesticides, Gross says that a safe alternative is increasingly critical. "This continued support from the National Science Foundation will help us take the final steps toward our goal — offering a safe and superior biopesticide that poses no threat to the farmers who handle the materials or to the consumers who buy their produce," Gross said.

In testing, the SyntheZyme product proved highly effective against the three major plant pathogen fungal groups that attack commercially important crops including potatoes, tomatoes, wheat, corn and rice.

The Phase II grant will allow SyntheZyme to complete additional research necessary to commercialize the biopesticide. Plans include optimizing the processes for yeast fermentation and product production, conducting field trials and performing additional toxicity and biodegradation testing. <
'/>"/>

SOURCE Polytechnic Institute of New York University
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)...  Inhibikase Therapeutics, Inc., an emerging leader in ... present new results on its antiviral program to ... the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, ... the causative agent of Progressive Multifocal Leukoencephalopathy (PML). ... extended release formulation, can clear JC polyomavirus (JCV) ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Announces Clinical Trial Plans for 4Q07/1Q08, DALLAS, ... ACCP) provided today an update on the clinical,development ... prodrug, and,announced plans for additional human clinical trials ... ongoing clinical trial in recurrent ovarian,cancer patients, designed ...
... ... Study -, ... has initiated a multi-dose, Phase 2a clinical trial with,its monoclonal antibody ... dose-escalation study is,designed to evaluate the safety and tolerability of multiple ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma 2
(Date:5/23/2013)... who eat at fast-food restaurants are consuming significantly more ... worst offenders, a new study found. "Teens underestimate ... much as 34 percent, parents of school-age children by ... much as 20 percent," study lead researcher, Dr. Jason ... Wood Johnson Foundation, which helped fund the study. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
(Date:5/23/2013)... 2013 “Talk. They Hear You.” a ... parents to talk to children as young as nine ... launched today by the Substance Abuse and Mental Health ... conjunction with SAMHSA’s 2013 National Prevention Week—an annual health ... substance abuse and mental health issues. , SAMHSA’s latest ...
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... be tested in a clinical trial by a biomedical ... disease has failed to work with the same type ... results of a study by University of Florida researchers. ... with the Evelyn F. and William L. McKnight Brain ... of verifying promising research results before investing in clinical ...
Breaking Medicine News(10 mins):Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3
... News) -- Scientists report that mutating a single gene produced ... finding they say could one day lead to the development ... effective drugs to treat the disorder. Mutating the shank3 ... interaction in the mice, apparently caused by impaired communication between ...
... By Kathleen Doheny HealthDay Reporter , SATURDAY, March ... allergy to milk as quickly as experts previously have believed. ... allergy, just over a third outgrew it within 30 months. ... that found a much higher percentage of children outgrowing the ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, March ... an advisory panel to the U.S. Food and Drug ... and their removal "from the marketplace would benefit public ... Scientific Advisory Committee also said that menthols, minty flavor ...
... March 18 (HealthDay News) -- Women in smoke-free homes ... from breast cancer, new research shows. U.S. researchers ... rates of breast cancer incidence and death. States with ... fewer breast cancer deaths, particularly among younger premenopausal women. ...
... FRIDAY, March 18 (HealthDay News) -- Scientists who,ve uncovered the ... to control mosquito-borne diseases such as West Nile virus and ... than 100 proteins in the male sperm of Aedes ... dengue fever -- permanently alter female mosquitoes, tendencies to feed, ...
... The U.S. medical system is ill-prepared to cope with the ... suggests. Specifically, too few health care providers are adequately ... the report authors indicate. The observation is outlined in ... the state of HIV health care in the United States ...
Cached Medicine News:Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Report Highlights Shortage of HIV Care Providers in U.S. 2
... The Accustrip Strep A(ll) Test ... immunoassay for the rapid, qualitative ... antigen from throat swabs. The ... as an aid in the ...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: